Skip to main content

Bruker Corporation (BRKR) Stock Analysis

Momentum Cont setup

SellModerate Confidence

Healthcare · Medical Devices

Sell if holding. Engine safety override at $42.75: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 16%; Below-average business quality.

Bruker develops and distributes high-performance scientific instruments across four segments: BSI BioSpin (NMR/MRI), BSI CALID (mass spec, microbiology diagnostics), BSI NANO (X-ray, microscopy, metrology), and BEST (energy/superconductor). Revenue is internationally distributed... Read more

$42.750.0% A.UpsideScore 4.7/10#39 of 40 Medical Devices
QualityF-score9 / 9FCF yield3.27%
IncomeYield0.47%(5y avg 0.33%)Payout38.46%sustainable
Stop $39.76Target $42.76(analyst − 13%)A.R:R 0.0:1
Analyst target$49.15+15.0%13 analysts
$42.76our TP
$42.75price
$49.15mean
$35
$60

Sell if holding. Engine safety override at $42.75: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 16%; Below-average business quality. Chart setup: Trend continuation, RSI 68, MACD bullish. Score 4.7/10, moderate confidence.

Passes 7/10 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.

Val6.6Qual3.9Grw3.2Mom5.3Sent6.4Ins5.0Peer3.1Tech3.5Risk4.64.7OVERALL

Recent Developments — Bruker Corporation

Latest news

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards
No bull case signals
Risks
Target reached (0.0% upside)
Quality below floor (3.9 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)17.7
Mkt Cap$6.5B
EV/EBITDA16.6
Profit Mgn-0.3%
ROE-0.4%
Rev Growth2.7%
Beta1.12
Dividend0.47%
Rating analysts22

Quality Signals

Piotroski F9/9

Options Flow

P/C1.00neutral
IV54%elevated
Max Pain$70+63.7% vs spot

Concentration Risks(10-K Item 1A)

  • MEDIUMGeographicEurope36%
    10-K Item 1A: 'Our revenue from operations in Europe represented approximately 36% and 35% of total consolidated revenue for fiscal years 2025 and 2024'
  • MEDIUMGeographicAsia Pacific30%
    10-K Item 1A: 'Our revenue from operations in the Asia Pacific region represented approximately 30% and 29% of total consolidated revenue for fiscal years 2025 and 2024'

Material Events(8-K, last 90d)

  • 2026-04-10Item 5.02MEDIUM
    Falko Busse, President of Bruker BioSpin, agreed to transition duties around May 1, 2026 with employment ending October 31, 2026. Separation agreement provides ~$1,020,351 CHF in severance, pro-rated bonus, and unused vacation. No successor named.
    SEC filing →
  • 2026-04-01Item 5.02LOW
    Thierry L. Bernard (CEO of QIAGEN) appointed to Bruker's Board as Class III director effective April 1, 2026, serving until the 2027 Annual Meeting of Stockholders.
    SEC filing →
  • 2026-02-20Item 5.02LOW
    Dr. Cynthia Friend will not stand for re-election at 2026 Annual Meeting (no disagreement cited). Jack Phillips reclassified from Class III to Class II director effective February 19, 2026.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
2.3
Quality Rank
3.0
Value Rank
7.0

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Revenue Growth
3.2
Low model confidence on this dimension (33%).

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Support Resistance
2.2
Bollinger
3.0
52w Position
5.2

Unprofitable operations — net margin -0.3%. Quality floor flags this regardless of sector context.static

Roe
0.0
Net Margin
0.0
Roa
1.8
Operating Margin
2.5
Moat
4.6
Fcf Quality
4.7
Gross Margin
5.5
Current Ratio
5.7
Piotroski F
10.0
FCF-positive but moderate margins (FCF margin 6%, FCF yield 3.3%)No competitive moatStrong Piotroski F-Score: 9/9
GatesMomentum 5.3<5.5 (soft — BUY_NOW allowed but watch)A.R:R UPSIDE_EXHAUSTED (upside=0.0%)Death cross (50MA < 200MA)Momentum 5.3>=4.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 77d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARMomentum ContSuitability: Moderate
RSI
68 · Neutral
↑ 20D MA↑ 50D MA↑ 200D MADEATH CROSSSupport $33.80Resistance $45.24

Price Targets

$40
$43
A.Upside+0.0%
A.R:R0.0:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Target reached (0.0% upside)
! Quality below floor (3.9 < 4.0)

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-08-04 (77d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is BRKR stock a buy right now?

Sell if holding. Engine safety override at $42.75: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 16%; Below-average business quality. Chart setup: Trend continuation, RSI 68, MACD bullish. Prior stop was $39.76. Score 4.7/10, moderate confidence.

What is the BRKR stock price target?

Take-profit target: $42.76 (0.0% upside). Prior stop was $39.76. Stop-loss: $39.76.

What are the risks of investing in BRKR?

Target reached (0.0% upside); Quality below floor (3.9 < 4.0).

Is BRKR overvalued or undervalued?

Bruker Corporation trades at a P/E of N/A (forward 17.7). TrendMatrix value score: 6.6/10. Verdict: Sell.

What do analysts say about BRKR?

22 analysts cover BRKR with a consensus score of 3.9/5. Average price target: $49.

What does Bruker Corporation do?Bruker develops and distributes high-performance scientific instruments across four segments: BSI BioSpin (NMR/MRI),...

Bruker develops and distributes high-performance scientific instruments across four segments: BSI BioSpin (NMR/MRI), BSI CALID (mass spec, microbiology diagnostics), BSI NANO (X-ray, microscopy, metrology), and BEST (energy/superconductor). Revenue is internationally distributed with Europe (~36%), APAC (~30%), and US (~26%) of 2025 revenues; China contributed $475.8M. US academic funding reductions and delayed Chinese government stimulus are cited 2025 headwinds.

Related stocks: GMED (Globus Medical, Inc.) · DXCM (DexCom, Inc.) · PODD (Insulet Corporation) · ZBH (Zimmer Biomet Holdings, Inc.) · LIVN (LivaNova PLC)